A Phase 2, Open-label, Multicenter Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Subjects With Non-transfusion-dependent Thalassemia
Latest Information Update: 26 Sep 2024
At a glance
- Drugs Mitapivat (Primary)
- Indications Alpha-thalassaemia; Beta-thalassaemia; Thalassaemia
- Focus Proof of concept; Therapeutic Use
- Sponsors Agios Pharmaceuticals
- 13 Dec 2022 Results assessing the effect of mitapivat on markers of erythropoietic activity through Week 72, along with Hb and markers of hemolysis and iron homeostasis, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 10 Dec 2022 According to an Agios Pharmaceuticals media release, the company will host a live investor event o review the key clinical oral and poster presentations from this year ASH meeting.
- 10 Dec 2022 According to an Agios Pharmaceuticals media release, data from the study were presented in a poster presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.